Support molecular diagnosis for chronic and infectious diseases such as cancer and HIV
Inspired in the vision of creating social impact through science, the Jacinto Convit World Organization has a multidisciplinary team of professionals that work with commitment, communication and diversity of capabilities to help those that need it the most and make a positive impact in our society
Jacinto Convit World Organization (JCWO) is pleased to announce on Breast Cancer Awareness Day, the publication of their latest work “Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment” in Oncotarget. Currently, the combination of immunotherapies for the treatment of cancer is a powerful and promising therapeutic strategy, with much exciting work ahead that can lead to stronger and more efficient treatments. JCWO is advancing to develop pioneer work in breast cancer treatment, combining effective and last generation immunotherapies that can provide new options for patients. In this work we combine for the first time Dr. Jacinto Convit´s personalized breast cancer vaccine, ConvitVax, with the already commercialized checkpoint inhibitor anti-PD-1, in a murine model. The aim of this study was to further potentiate the anti-tumor effect of the ConvitVax in breast cancer. The results obtained strongly encourage us to continue pushing forward our efforts to develop the therapeutic vaccine and perform new cutting-edge studies on treatment combinations that may contribute in the future to a larger number of people affected by the disease
